{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:47:02Z","timestamp":1792262822866,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejca.2021.05.027","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:20:24Z","timestamp":1624692024000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Utility of the CPS\u00a0+\u00a0EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"153","author":[{"given":"Frederik","family":"Marm\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-2826","authenticated-orcid":false,"given":"Laura","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-3743","authenticated-orcid":false,"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-7387","authenticated-orcid":false,"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Hanusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-2226","authenticated-orcid":false,"given":"Bianca","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-1267","authenticated-orcid":false,"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.05.027_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.05.027_bib2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib4","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.027_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.027_bib6","doi-asserted-by":"crossref","first-page":"v67","DOI":"10.1093\/annonc\/mdx362.065","article-title":"OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1\/2 mutation (gBRCAm)","volume":"28","author":"Tutt","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.09.022","article-title":"Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy","volume":"53","author":"Marme","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.027_bib8","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1200\/JCO.2007.11.5352","article-title":"Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy","volume":"26","author":"Jeruss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib10","first-page":"JCO2003639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2008.20.3133","article-title":"Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer","volume":"27","author":"Untch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib12","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib13","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib14","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2012.45.0940","article-title":"Response-guided neoadjuvant chemotherapy for breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.027_bib16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib17","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib18","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","article-title":"Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)","volume":"24","author":"Gerber","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.027_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/annonc\/mdq713","volume":"22","author":"Untch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jnci\/dji206","article-title":"American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome","volume":"97","author":"Carey","year":"2005","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.027_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/sim.6370","article-title":"Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach","volume":"34","author":"Kang","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2021.05.027_bib26","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-GS5-01","article-title":"Abstract GS5-01: residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis","volume":"80","author":"Yau","year":"2020","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.027_bib28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-Term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.027_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-GS5-02","article-title":"Abstract GS5-02: detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): preplanned correlative results from clinical trial BRE12-158","volume":"80","author":"Radovich","year":"2020","journal-title":"Canc Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:04Z","timestamp":1760733244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"alternative-id":["S0959804921003373"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of the CPS\u00a0+\u00a0EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}